BOULDER, Colo., July 27, 2016 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2016 and hold a conference call to discuss those results on Thursday, August 4, 2016. Ron Squarer, Chief Executive Officer, will lead the call.

https://photos.prnewswire.com/prnvar/20121029/LA02195LOGO



    Date:                                    Thursday, August 4, 2016

    Time:                                    9:00 a.m. Eastern Time

    Toll-Free:                               (844) 464-3927

    Toll:                                    (765) 507-2598

    Pass Code:                                                  55520532

    Webcast, including Replay and Conference Call Slides:
    http://edge.media-server.com/m/p/9vx5kngz

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.



    CONTACT:                          Tricia Haugeto

                                      Array BioPharma Inc.

                                      (303) 386-1193

                                      thaugeto@arraybiopharma.com

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2016-on-august-4-2016-300305147.html

SOURCE Array BioPharma Inc.